XML 67 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Narrative (Details)
$ in Thousands
1 Months Ended
Oct. 30, 2018
USD ($)
shares
May 31, 2019
USD ($)
licensed_product
shares
Dec. 31, 2018
USD ($)
Sep. 30, 2011
USD ($)
Commitments and contingencies        
Number of licensed products | licensed_product   1    
License Agreements | Archemix | C5 Licensed Product | Achievement of specified clinical and regulatory milestones | Maximum        
Commitments and contingencies        
Amount to be paid on achievement of milestone       $ 56,500
License Agreements | Archemix | C5 Licensed Product | First indication | Maximum        
Commitments and contingencies        
Amount to be paid on achievement of milestone       30,500
License Agreements | Archemix | C5 Licensed Product | Second and third indication | Maximum        
Commitments and contingencies        
Amount to be paid on achievement of milestone       23,500
License Agreements | Archemix | C5 Licensed Product | Sustained delivery applications | Maximum        
Commitments and contingencies        
Amount to be paid on achievement of milestone       2,500
License Agreements | Archemix | C5 Licensed Product | Achievement of specified commercial milestones | Maximum        
Commitments and contingencies        
Amount to be paid on achievement of milestone       $ 22,500
RHO-adRP License Agreement | University of Florida Research Foundation (UFRF) | Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product        
Commitments and contingencies        
Amount to be paid on achievement of milestone     $ 23,500  
RHO-adRP License Agreement | University of Florida Research Foundation (UFRF) | Specified commercial sales milestones with respect to a licensed product        
Commitments and contingencies        
Amount to be paid on achievement of milestone     $ 70,000  
Inception 4        
Commitments and contingencies        
Contingent consideration arrangements, maximum amount $ 105,000      
Contingent consideration arrangements, maximum amount (in shares) | shares 7,200,000      
Contingent consideration arrangements, contingently issuable shares as a percentage of shares outstanding 19.90%      
Inception 4 | GA Product        
Commitments and contingencies        
Clinical and marketing approval milestones $ 45,000      
Inception 4 | Wet AMD Product        
Commitments and contingencies        
Clinical and marketing approval milestones $ 60,000      
Research and Development Expense | License Agreements | University Of Massachusetts (UMass) | miniCEP290 | Achievement of specified clinical and regulatory milestones        
Commitments and contingencies        
Payments for license fees   $ 14,750    
Shares issued for license fees (in shares) | shares   75,000    
Research and Development Expense | License Agreements | University Of Massachusetts (UMass) | miniCEP290 | Specified commercial sales milestones with respect to a licensed product        
Commitments and contingencies        
Payments for license fees   $ 48,000    
Research and Development Expense | BEST1 License Agreement | University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) | Primary Licensed Product | Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product        
Commitments and contingencies        
Payments for license fees   15,700    
Research and Development Expense | BEST1 License Agreement | University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) | Primary Licensed Product | Specified commercial sales milestones with respect to a licensed product        
Commitments and contingencies        
Payments for license fees   48,000    
Research and Development Expense | BEST1 License Agreement | University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) | Other Licensed Product | Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product        
Commitments and contingencies        
Payments for license fees   3,100    
Research and Development Expense | BEST1 License Agreement | University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) | Other Licensed Product | Specified commercial sales milestones with respect to a licensed product        
Commitments and contingencies        
Payments for license fees   $ 9,600